hydration room semaglutide IV Therapy IV Hydration, Peptides, Hyperbaric in

To find active trials near you, go to ClinicalTrials.gov and search for "retatrutide," or visit Eli Lilly's trial finder at trials.lilly.com

BPC-157 and dihexa are in that unresolved category

M.SheehanD

Phase 1 data published 2021, Phase 2 data published 2023 (NEJM), the Phase 3 program TRIUMPH is ongoing: TRIUMPH-1 , Phase 3 obesity without T2D (n=2,100), results Q4 2025 TRIUMPH-2 , Phase 3 obesity + T2D (n=1,800), results 2026 TRIUMPH-3 , Phase 3 obesity + CV disease (n=1,900), results 2026 TRIUMPH-4 , Phase 3 obesity + knee osteoarthritis, results 2026 TRIUMPH-OUTCOMES , Phase 3 cardiovascular outcome trial (n=15,000+), results 2027 to 2028 FDA approval is expected at the earliest 2026 to 2027 in the obesity indication, similarly for T2DM

Hydration/GI : nausea, vomiting, diarrhoea, reduced intakegiven explicit dehydration precautions in EU/US documents